Evidence map›Paper›PMID 41820693›Full record

ArticleDiscover mental health2026

The influence of group physical activity on oxytocin, empathy, affect, and stress in individuals with schizophrenia spectrum disorders in a single-arm, pilot and exploratory study.

Marco Zierhut, Inge Hahne, Niklas Bergmann, Sofie Grässer, Max Alt, Laura Töbelmann, Josefa Wohlthan, Viktoria Huber, Thi Minh Tam Ta, Malek Bajbouj and 2 more

Abstract read
In one paragraph

Article in Discover mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marco ZierhutDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. marco.zierhut@charite.de.
Inge HahneDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Niklas BergmannDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Sofie GrässerDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Max AltDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Laura TöbelmannDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Josefa WohlthanDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Viktoria HuberDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Thi Minh Tam TaDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Malek BajboujDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Eric HahnDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Kerem BögeDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research showed low plasma levels of the neuropeptide oxytocin in schizophrenia spectrum disorders (SSD), correlating with reduced empathy and negative symptoms. After oxytocin administration an increase in empathy was observed in healthy individuals, but the results are generally mixed. Endogenous oxytocin plasma levels increased after physical activity (PA). Due to the role of social factors in oxytocin’s effects, this study examined group-based PA in SSD and its effects. N = 34 individuals with SSD were recruited at Charité – Universitätsmedizin Berlin. Groups of up to six patients participated in a 30-minute manual-based PA session focusing on body tension and posture. Changes were assessed in plasma oxytocin, empathy, affect, and stress using self- and rater-based questionnaires. Oxytocin plasma levels significantly increased from baseline to post-participation in group-based PA. Moreover, significant reductions in negative affect (Positive and Negative Affect Scale), symptom-related distress, and increased contentment were found, as well as a trend toward a reduction of Personal distress on the Interpersonal Reactivity Index measuring empathy. In this exploratory study group PA resulted in elevations in endogenous oxytocin plasma levels. Secondary outcomes were mixed regarding empathy with only a trend toward reduction in Personal distress. Overall, group PA may have a stress-reducing effect, although it remains to be investigated whether oxytocin is the biological component in this process. Group PA could be a cost-effective adjunct treatment option for individuals with SSD. Future randomized controlled trials are needed to confirm effects and disentangle the interplay of PA, changes in oxytocin levels and symptoms in SSD.

Indexed as

AffectEmpathyOxytocinPhysical activitySchizophrenia spectrum disordersStress

Identifiers

PMID41820693
PMCPMC13066114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.